Growth & profitability
- Revenue has grown 10.0% per year over the past 5 years.
- Operating margin has contracted, at -343.6% in the latest year.
PTGX Financials Protagonist Therapeutics, Inc
12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $46M | -$130M | 0.0% | -343.6% | $56M | — | $128M |
| 2024 | $434M | $275M | 0.0% | 58.2% | $183M | — | $97M |
| 2023 | $60M | -$79M | 0.0% | -156.1% | -$71M | — | $187M |
| 2022 | $27M | -$127M | 0.0% | -494.2% | -$109M | — | $126M |
| 2021 | $27M | -$126M | 0.0% | -460.0% | -$109M | — | $124M |
| 2020 | $29M | -$66M | 0.0% | -225.4% | -$73M | — | $117M |
| 2019 | $231000 | -$77M | 0.0% | -34857.6% | -$42M | $10M | $33M |
| 2018 | $31M | -$39M | 0.0% | -136.7% | -$50M | — | $82M |
| 2017 | $20M | -$37M | 0.0% | -188.9% | $3M | — | $106M |
| 2016 | — | -$37M | — | — | -$30M | — | $21M |
| 2015 | — | -$15M | — | — | -$15M | — | $4M |
| 2014 | — | -$11M | — | — | — | — | $9M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $56M | $4M | 0.0% | -6.5% | -$49M | — | $194M |
| Dec '25 | $7M | -$44M | 0.0% | -677.1% | -$37M | — | $128M |
| Sep '25 | $5M | -$39M | 0.0% | -985.2% | -$2M | — | $114M |
| Jun '25 | $6M | -$35M | 0.0% | -758.0% | -$30M | — | $169M |
| Mar '25 | $28M | -$12M | 0.0% | -68.2% | $125M | — | $140M |
| Dec '24 | $171M | $132M | 0.0% | 74.3% | -$29M | — | $97M |
| Sep '24 | $5M | -$33M | 0.0% | -886.7% | -$29M | — | $131M |
| Jun '24 | $4M | -$31M | 0.0% | -931.0% | $269M | — | $356M |
| Mar '24 | $255M | $207M | 0.0% | 80.9% | -$28M | — | $173M |
| Dec '23 | $60M | $27M | 0.0% | 38.4% | $17M | — | $187M |
| Sep '23 | $0 | -$34M | — | — | -$27M | — | $231M |
| Jun '23 | $0 | -$38M | — | — | -$26M | — | $235M |
| Mar '23 | $0 | -$34M | — | — | -$34M | — | $128M |
| Dec '22 | $0 | -$34M | — | — | -$32M | — | $126M |
| Sep '22 | $0 | -$31M | — | — | -$25M | — | $153M |
| Jun '22 | $859000 | -$41M | 0.0% | -4824.6% | -$14M | — | $120M |
| Mar '22 | $26M | -$21M | 0.0% | -82.1% | -$38M | — | $98M |
| Dec '21 | $9M | -$37M | 0.0% | -429.6% | -$27M | — | $124M |
| Sep '21 | $10M | -$34M | 0.0% | -329.8% | -$29M | — | $121M |
| Jun '21 | $2M | -$31M | 0.0% | -1363.4% | -$24M | — | $192M |
Valuation over time
How the market has priced PTGX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 9.0× (Dec '24) to 21.0× (Nov '25).
- The price-to-sales ratio has risen from 55.7× (Mar '23) to 171.5× (Jun '26).
P/E
P/S
Frequently asked questions
Is PTGX growing its revenue and profit?
Over the past 5 years, Protagonist Therapeutics, Inc's revenue has grown 10.0% per year. These are computed facts, not advice.
How much debt does PTGX have?
As of FY2025, Protagonist Therapeutics, Inc reported — of total debt against $128M of cash.
What is PTGX's profit margin?
In FY2025, gross margin was —, operating margin -343.6%, and net margin -282.8%.
What is PTGX's P/E ratio?
As of Jun '26, Protagonist Therapeutics, Inc traded at a price-to-earnings ratio of about 21.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.